Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Alector, Inc. (Nasdaq: ALEC) announced on May 27, 2022, that its board approved an inducement equity grant for Gary Romano, M.D., Ph.D., its new Chief Medical Officer. The grant includes inducement stock options for 369,000 shares and restricted stock units (RSUs) for 92,250 shares, aligned with the 2022 Inducement Equity Incentive Plan. The options have an exercise price of $9.20 per share and vest over four years, while the RSUs vest quarterly over three years, starting September 1, 2022. This move aims to attract talent amid growing operations in immuno-neurology.
- Inducement equity grant of 369,000 stock options and 92,250 RSUs to attract new talent.
- Stock options have an exercise price of $9.20, equal to the market price, indicating alignment with shareholder interests.
- Vesting schedule for stock options and RSUs incentivizes long-term commitment and performance.
- None.
SOUTH SAN FRANCISCO, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector’s board of directors granted Gary Romano, M.D., Ph.D., the company’s newly-hired Chief Medical Officer, an inducement equity grant on May 27, 2022, consisting of inducement stock options to purchase an aggregate of 369,000 shares of the company’s common stock and inducement restricted stock units, or RSUs, covering an aggregate of 92,250 shares of the company’s common stock. These inducement stock options and inducement RSUs are subject to the terms of Alector’s 2022 Inducement Equity Incentive Plan and related forms of agreements and were granted as inducements material to new employees entering into employment with Alector in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.
Contacts:
1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com
Argot Partners (investors)
Eric Kasper/Carrie McKim
Argot Partners
212.600.1902
alector@argotpartners.com
FAQ
What is Alector's recent equity grant for new executives?
What is the exercise price for Alector's stock options granted to the new CMO?
What is the vesting schedule for Alector's inducement stock options?
When do Alector's restricted stock units (RSUs) vest?
